Articles related to ANTIPSYCHOTICS

Effective management of tardive dyskinesia requires early prevention with second-generation antipsychotics and the use of VMAT2 inhibitors like deutetrabenazine and valbenazine, which offer the highest quality evidence for reducing symptoms.

Research presented at the APA 2024 Annual Meeting sheds light on innovative treatments and the multifaceted burden of anxiety disorders, highlighting significant advances in managing GAD and related comorbidities.

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.

The Johns Hopkins Clozapine Consultation Clinic is addressing the critical underutilization of clozapine in treatment-resistant schizophrenia, providing essential support and education for healthcare providers in navigating its benefits and risks.

LYN-005 represents a breakthrough in schizophrenia management, showing promise in maintaining therapeutic levels and symptom control with just once-weekly dosing.

The JEWEL study has demonstrated that lurasidone treatment in patients with schizophrenia results in significant improvements in social functioning, with notable progress observed from the early stages of treatment and sustained benefits over a 12-week extension period.